- authorisedTherapeutic exploratory (Phase II)
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)
This study is testing a new medicine called AGA2115 for adults with osteogenesis imperfecta (brittle bone disease). Researchers want to see if different doses can help strengthen bones in the lower back over 12 months, and check how safe the medicine is compared to a dummy drug.
Netherlands · France · Denmark - recruitingTherapeutic use (Phase IV)
Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid
This study looks at different treatments for Osteogenesis Imperfecta (brittle bone disease) in adults. Researchers want to understand which treatments best reduce bone breaks over several years. It's an ongoing study tracking real-world results.
France · Ireland · Netherlands - recruitingPhase II
Losartan for older adolescents and adults with osteogenesis imperfecta
This study is testing whether a common blood pressure tablet called losartan can strengthen bones and muscles in people with osteogenesis imperfecta (brittle bone disease). It is open to people aged 16 and older in the UK and involves taking the medication every night for 24 weeks.
United Kingdom · England · Scotland - active not recruitingPHASE3
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
This study is looking at a new medicine called romosozumab for children and teenagers aged 5-17 with Osteogenesis Imperfecta (brittle bone disease). It wants to see if romosozumab is better than existing bisphosphonate medicines at preventing broken bones and improving bone strength over 12 months.
United States · Australia · Austria - active not recruiting
Urinary Biomarkers of OI Pathobiology
This study looks at chemicals in urine to understand Osteogenesis Imperfecta (OI), a condition causing brittle bones. Researchers want to find easier ways to classify OI by studying how it affects the body at a chemical level. This could help tailor treatments better in the future.
United States · Canada - active not recruiting
Dental Malocclusion and Craniofacial Development in OI
This study looks at teeth and jaw problems in people with Osteogenesis Imperfecta (OI), a condition causing brittle bones. Researchers want to understand these issues better to improve dental health and quality of life for people with OI.
United States · Canada - active not recruitingPHASE2, PHASE3
Setrusumab vs Placebo for Osteogenesis Imperfecta
This study is testing a new medicine, Setrusumab, for people aged 5-25 with Osteogenesis Imperfecta (brittle bone disease). It aims to see if Setrusumab can reduce bone fractures compared to a dummy treatment (placebo) and find the best dose.
United States · Australia · Canada - active not recruitingNA
Clear Aligners for the Treatment of Dental Malocclusion in OI
This study looks at using clear aligners (like Invisalign) to straighten teeth for people with Osteogenesis Imperfecta (OI). It aims to find out if this treatment is safe and works well for those with mild to moderate teeth misalignment and no previous brace treatment. We hope to develop better guidelines for dental care in OI.
United States · Canada